Degnan Chris
SEC insider (Form 3/4/5 filer). CIK 0001741968. Chief Financial Officer at UroGen Pharma Ltd. (URGN). 7 reported Form 4/5 transactions since Sep 2024; latest on Oct 8, 2026. Located in PRINCETON, NJ.
Companies Degnan Chris has filed insider reports for
- UroGen Pharma Ltd. (URGN): Officer, Chief Financial Officer
Degnan Chris
CIK: 0001741968
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
UroGen Pharma Ltd.
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Oct 8, 2026URGN
UroGen Pharma Ltd.
ExerciseDirect4.5K shares- - Oct 8, 2026URGN
UroGen Pharma Ltd.
SaleDirect2.2K shares at avg. $36.69$81K - Jan 31, 2026URGN
UroGen Pharma Ltd.
AwardDirectRestricted Stock Units
32.6K shares- - Oct 8, 2025URGN
UroGen Pharma Ltd.
SaleDirect2.2K shares at avg. $16.85$37K - Oct 8, 2025URGN
UroGen Pharma Ltd.
ExerciseDirect4.5K shares- - Oct 8, 2024URGN
UroGen Pharma Ltd.
AwardDirectRestricted Stock Units
13.5K shares- - Oct 8, 2024URGN
UroGen Pharma Ltd.
AwardDirectEmployee Stock Option (right to buy)
74.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 8, 2026 | URGN UroGen Pharma Ltd. | Exercise | 4,483 | - | $0 | Direct |
| Oct 8, 2026 | URGN UroGen Pharma Ltd. | Sale | 2,202 | $36.69 | $80,791 | Direct |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | Award Restricted Stock Units | 32,609 | - | - | Direct |
| Oct 8, 2025 | URGN UroGen Pharma Ltd. | Sale | 2,203 | $16.85 | $37,121 | Direct |
| Oct 8, 2025 | URGN UroGen Pharma Ltd. | Exercise | 4,483 | - | - | Direct |
| Oct 8, 2024 | URGN UroGen Pharma Ltd. | Award Restricted Stock Units | 13,450 | - | - | Direct |
| Oct 8, 2024 | URGN UroGen Pharma Ltd. | Award Employee Stock Option (right to buy) | 74,142 | - | - | Direct |
1-7 of 7 transactions